UK markets closed

Oncimmune Holdings Plc (ONC.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
17.500.00 (0.00%)
At close: 01:35PM BST

Oncimmune Holdings Plc

1 Park Row
Leeds LS1 5AB
United Kingdom

Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Martin John GouldstoneCEO & DirectorN/AN/A1967
Mr. Martin HudsonFin. DirectorN/AN/AN/A
Mr. Ron KirschnerCOO, Gen. Counsel & Company Sec.N/AN/A1979
Prof. Tariq Sethi M.D., B.Sc., M.A., Ph.D., FRCPChief Scientific OfficerN/AN/AN/A
Ms. Cléa RosenfeldHead of Investor RelationsN/AN/AN/A
Mr. Maarten BrusseChief Commercial Officer of AsiaN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a immunodiagnostic test for detecting and identifying lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc has a collaboration with Siemens Healthineers AG. Oncimmune Holdings plc was incorporated in 2015 and is based in Leeds, the United Kingdom.

Corporate governance

Oncimmune Holdings Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.